Hanna Ritzén is currently Managing Director Research and Development at Mercodia AB, a Swedish biotech company that specializes in the development and production of ELISA assays as well as bioanalytical services, within the area of metabolic disorders. She started her career at Mercodia as a Product Development scientist in 2002, and since then held different positions within Research and Development. She has been involved in the CAPA process and life cycle management of the internally developed and produced ELISA kits, which are used to detect biomarkers in both human and animal samples.
Today, she is responsible for product development of commercial IVD and RUO ELISA kits, post market surveillance, and assay development, validation, and sample analysis under the umbrella of Bioanalytical Services. She is also involved in the clinical laboratory test standardization and harmonization of Insulin and C-peptide biomarker methods administered by American Association of Clinical Chemistry.
Monday, November 4
3:00 PM – 3:15 PM
Tuesday, November 5
12:00 PM – 1:00 PM